Cases & Deals

ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technology

Clients ToolGen, Inc.

Jones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.